Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AgenT-797 |
Synonyms | |
Therapy Description |
AgenT-797 is an HLA-unmatched allogeneic invariant natural killer T-cell (iNKT) therapy, which potentially induces antitumor immune activity (Cancer Res (2023) 83 (8_Supplement): CT275, PMID: 38321023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AgenT-797 | AgenT797|AgenT 797 | AgenT-797 is an HLA-unmatched allogeneic invariant natural killer T-cell (iNKT) therapy, which potentially induces antitumor immune activity (Cancer Res (2023) 83 (8_Supplement): CT275, PMID: 38321023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05108623 | Phase I | AgenT-797 AgenT-797 + Nivolumab AgenT-797 + Pembrolizumab | A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors | Completed | USA | 0 |